-
Exposure to specific solvents, and trichloroethylene in particular, is associated with an increased risk of Parkinson's disease.
-
The prevalence of chronic heart failure has steadily increased with improvements in survival rates for cardiac patients; however, heart failure remains a disorder whose typically progressive course worsens quality of life, and thus far has defied most conventional medical approaches. New ideas leading to new treatments are needed. The researchers behind this small intervention trial examined the effect of repeated sauna therapy on exercise tolerance in people with congestive heart failure and found significant benefits.
-
A 57-year-old postmenopausal librarian, who is 1-year post diagnosis of a stage II invasive cancer of the right breast, is found to be estrogen- and progesterone-receptor positive, and Her2neu negative with one positive axillary node.
-
A new angiotensin ii receptor blocker (ARB) and the thiazide diuretic, chlorthalidone, has been approved as a fixed combination for the treatment of hypertension.
-
There is perhaps no greater public health passion than that for fighting cancer. There is also perhaps no greater confusion than that surrounding nutrition and cancer. Public "cancer scares" regarding environmental exposures and alternative treatments often capture the public's attention.
-
In people without known cardiovascular disease, an increase in resting heart rate with age was associated with an increased risk of death.
-
A drug has been approved to treat high plasma levels of methotrexate. Glucarpidase is a bacterial enzyme produced by recombinant DNA technology using genetically modified Exherichia coli. Glucarpidase is a carboxypeptidase enzyme that metabolizes methotrexate to its inactive metabolites. It is marketed by BTG International Inc. as Voraxaze.
-
Right-sided MCL-1 monitoring lead rhythm strip. Why might beats #4 through #7 be wide?
-
There is still some debate about the relationship between being overweight and cardiovascular (CV) health, since among overweight individuals there is great diversity in levels of CV fitness as well as CV risk factors (e.g., hypertension, diabetes, dyslipidemia).
-
Among patients with coronary heart disease and LDL-cholesterol levels less than 70 mg/dL, there is no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up, despite improvements in HDL-cholesterol and triglyceride levels.
